In Chinese adults with overweight or obesity, once weekly #GLP glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 48 weeks, led to clinically relevant #weightloss in the Cagrilintide is a long acting amylin analog that regulates appetite, gastric emptying, and glucagon secretion to treat obesity and related metabolic disorders. There are 2 pathways cagrilintide works: #1 is the Amylin pathway Emerging incretin and multi agonist based treatments the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio kidney liver metabolic diseases and beyond Metabolism Clinical and Experimental Efficacy and safety of incretin co agonists: Transformative advances in cardiometabolic healthcare